The Michael Bloomberg family office: Willett Advisors

Michael Bloomberg, the entrepreneur, politician & philanthropist

Michael Bloomberg began his career on Wall Street in 1966 at the investment bank Salomon Brothers. 15 years later, he founded Bloomberg LP, which has become a major global information and technology company. Its annual revenues are estimated at around $12 billion. Bloomberg’s wealth is based on the company’s success. To date, he still owns 88% of the company. As a result, Bloomberg’s wealth is estimated at around $106 billion, making him one of the richest people in the world.

In addition to his business success, Michael Bloomberg was the mayor of New York City between 2002 and 2013 and wanted to become president of the United States in 2020. Finally, Bloomberg is a very active philanthropist, having donated more than $17 billion over the course of his life.

About Willett Advisors: The Bloomberg single family office

The Michael Bloomberg Family office Willet Advisors is based in New York City. Regarding Michael Bloomberg the Family Office mainly coordinates his philanthropic assets, like his Giving Pledge which he joined together with Bill Gates and Warren Buffet. Next, its philanthropic arm Willet Advisors invests in Public Markets, Hedge Funds, Private Equity and Credit, Real Assets, and Direct Investments. In the past Willet Advisors investet Start-ups like TraceLink or Y Combinator.  Furthermore, the Family Office has stakes in the Unicorn Circle. A company that created the USDC, a digital currency backed by the US dollar. The latest investments of the Michael Bloomberg Family office are focused on the healthcare sector containing companies such as Scorpion Therapeutics, Carmot Therapeutics, and Neurona Therapeutics.

The Latest investment of Willet Advisors

Scorpion Therapeutics, a clinical-stage oncology company, recently secured $150 million in Series C financing, co-led by Frazier Life Sciences and Lightspeed Venture Partners and support from Willett Advisors. The funding will support the clinical advancement of Scorpion’s leading program, STX-478, a treatment against mutated breast cancer and other solid tumors. Scorpion also plans to expand its portfolio of precision oncology therapies, leveraging its proprietary small molecule discovery platform. The financing strengthens Scorpion’s position in the precision oncology field, aiming to improve outcomes for cancer patients with targeted, highly selective therapies.

Source: Businesswire

Picture Source: Michael Discenza via Unsplash